Oncology >2009 Cancer Summit - Lung, Head & Neck, Breast, Gastrointestinal and Colorectal Cancers - Hilton Head, SC > Agenda

Agenda

July 23-25, 2009

Hilton Head, SC

2009 Cancer Summit: Lung, Head & Neck, Breast, and Gastrointestinal and Colorectal Cancers Hilton Oceanfront Resort, 23 Ocean Lane, Hilton Head Island, SC - July 23-25, 2009
Lung, Head &Neck Cancers - Thursday July 23, 2009
6:00 AM	Continental Breakfast and Registrations
6:55 AM	Welcome and Introductions	Chandra P. Belani, MD
State of the Art Lectures Chair: Chandra P. Belani, MD
7:00 AM	Non Small-Cell Lung Cancer: Recent Advances and Changing Treatment Paradigms	Paul Bunn, MD
7:20 AM	Combined Modality Therapy for Lung, Head & Neck Cancers	Walter Curran, MD
7:40 AM	Small Cell Lung Cancer: Recent Developments and Incorporation of Novel Agents	Ramaswamy Govindan, MD
8:00AM	Panel Discussion
EGFR and VEGF Targeted Agents Session Chair: Suresh Ramalingam, MD
8:20 AM	Advanced and Metastatic Non Small-Cell Lung Cancer: Implications of Bevacizumab, and Histology	Corey Langer, MD
8:40 AM	EGFR Tyrosine Kinase Inhibitors and Monoclonal Antibodies: Present Status and Future Perspectives, Molecular Markers and Patient Selection	Edward Kim, MD
9:00 AM	Other VEGF Targeted Agents and Multikinase Inhibitors in the Treatment of Lung Cancer	Suresh Ramalingam, MD
9:20 AM	Panel Discussion
9:40 AM	Break
9:50 AM	Cooperative Group Strategies in Lung Cancers	Suresh Ramalingam, MD
10:10 AM	Individualizing Chemotherapy and Targeted Therapy for Patients with Lung Cancer	George Simon, MD
10:30 PM	Implications of Proteomics and Genomics in the Management of Lung cancer	David Harpole, MD
10:50 AM	Panel Discussion
Emerging Novel Agents Chair: Chandra P. Belani, MD
11:10 PM	Emerging Role of Targeted nab-Paclitaxel, Bortezomib, and HDAC Inhibitors in Lung Cancer	Chandra P. Belani, MD
11:30 PM	New Systemic Therapies for the Treatment of Head & Neck Cancers	Ezra Cohen, MD
11:50 AM	Emerging Novel Agents in Lung and Head & Neck Cancer (Farletuzumab,TRAIL and mTOR Inhibitors, MEK Inhibitors, AKT Inhibitors, IGF-IR Antibodies, Small Molecules Inhibitors, and C-Met Inhibitors	Fadlo Khuri, MD
12:10 PM	Panel Discussion
12:30 PM	Closing Remarks & Adjourn	Chandra P. Belani, MD
12:35 PM	Lunch
Breast Cancer - Friday - July 24, 2009
6:00 AM	Continental Breakfast and Registration
6:30 AM	Welcome and Introductions	Mark Pegram, MD
State of the Art Lectures Chair: Mark Pegram, MD
7:00 AM	State of the Art: Breast Cancer Therapy in 2009	Mark Pegram, MD
7:20 AM	Management of Women at High Risk of Breast Cancer	Kevin Hughes, MD
8:00 AM	Role of Molecular Profiling of Breast Cancer	Charles Perou, PhD
Adjuvant and Hormonal Therapies of Breast Cancer Chair: Aman Buzdar, MD
8:20 AM	Optimizing Adjuvant Hormonal Therapy in Breast Cancer: Current Status	Aman Buzdar, MD
8:40 AM	Strategies to Treat Bone Loss in Women With Breast Cancer	Adam Brufsky, MD
9:00 AM	Predictive and Prognostic Markers for Response and Survival in Breast Cancer	Jeffrey Ross, MD
9:20 AM	Panel Discussion
9:40 AM	Break
Targeting VEGF and EGFR in Breast Cancer Chair: Mark Pegram, MD
9:50 AM	Role of VEGF and VEGFR Targeted Therapy for Breast Cancer	M. Jahanzeb, MD
Radiation Therapy Approaches Chair: Lawrence Solin, MD
10:10 AM	New Insights into Optimizing Local Control in Breast Cancer	Lawrence Solin, MD
10:30 PM	Accelerated Hypofractionated Breast Radiation Therapy: Safety and Efficacy Issues	Alphonse Taghian, MD
10:50 AM	Panel Discussion
Emerging Novel Agents and Supportive Therapy Chair: Mark Pegram, MD
11:10 PM	Novel Biologic Agents with Clinical Promise in the Treatment of Breast Cancer	Mark Pegram, MD
11:30 PM	Therapeutic Intervention for Patients with Triple Negative Breast Cancer	Brian Leyland-Jones, MD
11:50 AM	Supportive Care in the Management of Breast Cancer: Therapy Related Toxicities	Jeffrey Crawford, MD
12:10 PM	Panel Discussion
12:30 PM	Closing Remarks & Adjourn	Mark Pegram, MD
12:35 PM	Lunch
Gastrointestinal/Colorectal Cancers - Saturday – July 25, 2009
6:30 AM	Continental Breakfast
6:55 AM	Opening Remarks and Introductions	Axel Grothey, MD
State of the Art Lectures Chair: Axel Grothey, MD
7:00 AM	Chemotherapy for Advanced Colorectal Cancer: An Update	Axel Grothey, MD
7:20 AM	Adjuvant Chemotherapy for Colorectal Cancer: New Strategies	Sharlene Gill, MD
7:40 AM	Predictive and Prognostic Markers in Colorectal Cancer Beyond KRAS	Heinz-Josef Lenz, MD
8:00 AM	Novel Targets for Colorectal Cancer: New Horizons	Ramesh Ramanathan, MD
Targeting Angiogenesis Chair: Axel Grothey, MD
8:40 AM	Role of VEGFR Small Molecule Inhibitors in Colorectal Cancer	Scott Kopetz, MD
9:00 AM	Administering Angiogenesis Inhibitors to Patients with Colorectal Cancer: Safely Issues	Axel Grothey, MD
9:20 AM	Panel Discussion
9:40 AM	Break
Targeting the EGFR Pathway Chair: Heinz-Josef Lenz, MD
9:50 AM	Role of EGFR Inhibitors in the Treatment of Colorectal Cancer: Integration with Chemotherapy	Heinz Josef Lenz, MD
10:10 AM	Update on Ongoing Clinical Trials with EGFR inhibitors	Cathy Eng, MD
10:30 PM	Toxicities Associated with EGFR Inhibitors: Management Strategies	Mario Lacouture, MD
10:50 AM	Panel Discussion
Advances in Gastrointestinal Malignancies Chair: Melanie Thomas, MD
11:10 PM	Advances in the Treatment Options for Hepatocellular Carcinoma	Melanie Thomas, MD
11:30 PM	Update on Treatment Options for Esophageal, Gastric and Pancreatic cancers	Milind Javle, MD
11:50 AM	Surgery for Liver-Limited Metastases of Colorectal Cancer	Michael Kendrick, MD
12:10 PM	Panel Discussion
12:30 PM	Closing Remarks & Adjourn	Axel Grothey, MD
12:35 PM	Lunch

Agenda

July 23-25, 2009

Hilton Head, SC

International Cancer Network, serving internationally